BRAF and melanoma: In the context of clinical practice, while dealing with individuals who are suffering from a mutation in the BRAF gene in melanoma, the administration of encorafenib in conjunction with binimetinib has demonstrated favorable effectiveness and safety outcomes when compared to Vemurafenib usage as a standalone therapy [62].